N M Vora1,2, L A Orciari2, M Niezgoda2, G Selvaggi3, V Stosor4, G M Lyon5, R M Wallace1,2, J Gabel6, D R Stanek7, P Jenkins7, M Shiferaw2, P Yager2, F Jackson2, C A Hanlon2, I Damon2, J D Blanton2, S Recuenco2, R Franka2. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. 2. Poxvirus and Rabies Branch, CDC, Atlanta, Georgia, USA. 3. Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. 4. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 5. Emory University School of Medicine, Atlanta, Georgia, USA. 6. Georgia Department of Public Health, Atlanta, Georgia, USA. 7. Florida Department of Health, Tallahassee, Florida, USA.
Abstract
BACKGROUND: The rabies virus causes a fatal encephalitis and can be transmitted through organ transplantation. In 2013, a man developed rabies 18 months after receiving a kidney from a donor with rabies, who was not known to have been infected when the organs were procured. Three additional persons who received organs from the same donor (liver, kidney, heart), all of whom were not vaccinated for rabies before transplantation, received rabies post-exposure prophylaxis (PEP) with rabies immune globulin and 5 doses of rabies vaccine as soon as the diagnosis of rabies was made in the donor (18 months after their transplant surgeries). We describe their clinical management. METHODS: As the 3 recipients were all on immunosuppressive medications, post-vaccination serologic testing was performed using the rapid fluorescent focus inhibition test to measure rabies virus neutralizing antibodies (RVNAs). An acceptable antibody response to administration of rabies vaccine was defined as detection of RVNAs at a concentration ≥0.1 IU/mL from a serum specimen collected ≥7 days after the fifth vaccine dose. RESULTS: All 3 recipients demonstrated an acceptable antibody response despite their immunosuppressed states. More than 36 months have passed since their transplant surgeries, and all 3 recipients have no evidence of rabies. CONCLUSIONS: The survival of 3 previously unvaccinated recipients of solid organs from a donor with rabies is unexpected. Although the precise factors that led to their survival remain unclear, our data suggest that PEP can possibly enhance transplant safety in settings in which donors are retrospectively diagnosed with rabies.
BACKGROUND: The rabies virus causes a fatal encephalitis and can be transmitted through organ transplantation. In 2013, a man developed rabies 18 months after receiving a kidney from a donor with rabies, who was not known to have been infected when the organs were procured. Three additional persons who received organs from the same donor (liver, kidney, heart), all of whom were not vaccinated for rabies before transplantation, received rabies post-exposure prophylaxis (PEP) with rabies immune globulin and 5 doses of rabies vaccine as soon as the diagnosis of rabies was made in the donor (18 months after their transplant surgeries). We describe their clinical management. METHODS: As the 3 recipients were all on immunosuppressive medications, post-vaccination serologic testing was performed using the rapid fluorescent focus inhibition test to measure rabies virus neutralizing antibodies (RVNAs). An acceptable antibody response to administration of rabies vaccine was defined as detection of RVNAs at a concentration ≥0.1 IU/mL from a serum specimen collected ≥7 days after the fifth vaccine dose. RESULTS:All 3 recipients demonstrated an acceptable antibody response despite their immunosuppressed states. More than 36 months have passed since their transplant surgeries, and all 3 recipients have no evidence of rabies. CONCLUSIONS: The survival of 3 previously unvaccinated recipients of solid organs from a donor with rabies is unexpected. Although the precise factors that led to their survival remain unclear, our data suggest that PEP can possibly enhance transplant safety in settings in which donors are retrospectively diagnosed with rabies.
Authors: U Thisyakorn; C Pancharoen; K Ruxrungtham; S Ubolyam; P Khawplod; T Tantawichien; P Phanuphak; H Wilde Journal: Clin Infect Dis Date: 2000-01 Impact factor: 9.079
Authors: Arjun Srinivasan; Elizabeth C Burton; Matthew J Kuehnert; Charles Rupprecht; William L Sutker; Thomas G Ksiazek; Christopher D Paddock; Jeannette Guarner; Wun-Ju Shieh; Cynthia Goldsmith; Cathleen A Hanlon; James Zoretic; Bernard Fischbach; Michael Niezgoda; Waleed H El-Feky; Lillian Orciari; Edmund Q Sanchez; Anna Likos; Goran B Klintmalm; Denise Cardo; James LeDuc; Mary E Chamberland; Daniel B Jernigan; Sherif R Zaki Journal: N Engl J Med Date: 2005-03-17 Impact factor: 91.245
Authors: C K Warner; S R Zaki; W J Shieh; S G Whitfield; J S Smith; L A Orciari; J H Shaddock; M Niezgoda; C W Wright; C S Goldsmith; D W Sanderlin; P A Yager; C E Rupprecht Journal: Am J Trop Med Hyg Date: 1999-03 Impact factor: 2.345
Authors: D L Noah; C L Drenzek; J S Smith; J W Krebs; L Orciari; J Shaddock; D Sanderlin; S Whitfield; M Fekadu; J G Olson; C E Rupprecht; J E Childs Journal: Ann Intern Med Date: 1998-06-01 Impact factor: 25.391
Authors: Céline M Gossner; Alexandra Mailles; Inma Aznar; Elina Dimina; Juan E Echevarría; Siri Laura Feruglio; Heidi Lange; Francesco Paolo Maraglino; Patrizia Parodi; Jurijs Perevoscikovs; Yves Van der Stede; Tamás Bakonyi Journal: Euro Surveill Date: 2020-09